Custom Services order now ship next day


For many years, Creative Biolabs has devoted itself to developing immunotherapy in hematology to bring effective treatments to people suffering from hematonosis. Now, we can provide bispecific antibody (BsAb) development services for this purpose.

Figure: Factors in the coagulation cascade (Cardiovascular Research, 2014)

We have been systematically studying blood diseases including some kinds of blood cancers, such as chronic lymphocytic leukemia (CLL), B cell acute lymphoblastic leukemia (B cell ALL), acute myeloid leukemia (AML), and hemophilia, including hemophilia A and hemophilia B. For these diseases, immunotherapy and gene therapy are more potential treatment strategies. And abundant BsAbs have been developed or used in clinical trials. In the treatment of hemophilia A, the FIXa/FX BsAb (RG6013/ACE910) has been engineered to bring two cognate antigens into one complex, mimicking the FVIII cofactor function that is deficient in patients with this disease. We can also design and develop BsAbs targeting antigens that play critical roles in disease processes, and these BsAbs can be further applied in clinical fields of hematonosis including blood cancers and hemophilia.

According to every client`s individual requirements, experts from Creative Biolabs can offer you expected BsAbs with high quality and purity, which can be used in both scientific and clinical researches.


  1. Henri M.H. Spronk, et al. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovascular Research (2014) 101, 344–351.

For research use only. Not intended for any clinical use.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0

    Go to compare